


Supplementary Table 1. Oligonucleotide primer list.







Primer Name	RefSeq Accession No.	Sequence (5' to 3')
ATF4	NM_182810.2	CTCCAGCGACAAGGCTAAGG
		CATTTTCTCCAACATCCAATCTGT
CD36	NM_001001547.2	CAAAATCTTCTATGTTCCAAGTCAGA
		CCATCTGCAGTATTGTTGTAAGGATA
CHOP	NM_001195053.1	GAGAGAGTGTTCAGAAGGAAGTGT
		CCGAAGGAGAAAGGCAATGA
ERO-1	NM_019891.3	TGTTTCAAGCCTCGATCTGTTTAT
		AGACACAAACCTTCTAGCCATGTG
HIF1 α	NM_001530.3	TGTGTGAATTACGTTGTGAGTGGTAT
		CCGGTTTAAGGACACATTCTGTT
18S rRNA	M10098.1	CGAACGTCTGCCCTATCAACTT
		ACCCGTGGTCACCATGGTA

BIORAD Primer Name	Unique Assay ID	Amplicon Context Sequence
RPS18	qHsaCED0037454	GTGGAACGTGTGATCACCATTATGCAGA ATCCACGCCAGTACAAGATCCCAGACTG GTTCTTGAACAGACAGAAGGATGTAAAG GATGGAAAATACA
CD68	qHsaCED0007025	GTTTCTCCTGCCCCAGTGACCGGTCCATC TTGCTGCCTCTCATCATCGGCCTGATCCT TCTTGGCCTCCTCGCCCTGGTGCTTATTG CTTTCTGCATCATCCGGAGACGCC
IL-6	qHsaCID0020314	TGAAAAAGATGGATGCTTCCAATCTGGA TTCAATGAGGAGACTTGCTGGTAAAT CATCACTGGTCTTTTGGAGTTTGAGGTAT ACCTAGAGTACCTCCAGAACAGATTTGA GAGTAGTGAGGAACAAGCCAGAGCTGTG CAGATGAGTA
MCP-1	qHsaCID0011608	ACTGAAGCTCGCACTCTCGCCTCCAGCAT GAAAGTCTCTGCCGCCCTTCTGTGCCTGC TGCTCATAGCAGCCACCTTCATTCCCCAA GGGCTCGCTCAGCCAGATGCAATCAATG CCCCAGTCACCTGCTGTTATAACTTCACC AATAGGAAGATCTCAGTGCAGAGGCTCG CGAGCTAT
NLRP3	qHsaCID0036694	GCGATCAACAGGAGAGACCTTTATGAGA AAGCAAAAAGAGATGAGCCGAAGTGGG GTTTCAGATAATGCACGTGTTTCGAATCCC ACTGTGATATGCCAGGAAGACAGCATTG AAGAGGAGTGGATGGGTTTACTGGAGTA CCTTTCGAGA
PDGFB (PDGF β)	qHsaCID0016004	AGCTCGCCTCCAGAGTGGGAGCGGGTCA TGTTTCAGGTCCAACCTCGGCCCATCTTCC TCTCCGGGGTCTCCGTGCAGCAGGCGTT GGAGATCATCAAAGGAGCGGATCGAGTG GTC
TLR4	qHsaCED0037607	CAAGATTCAAAGTATTTATTGCACAGAC TTGCGGGTTCTACATCAAATGCCCTACT

		CAATCTCTCTTTAGACCTGTCCCTGAACC CTATGAACTTTATCCAACCAGGTGCATTT AAAGA
VEGFA (VEGF α)	qHsaCED0006937	TGGTGAAGTTCATGGATGTCTATCAGCG CAGCTACTGCCATCCAATCGAGACCCTG GTGGACATCTTCCAGGAGTACCCTGATG AGATCGAGTACATCTTCAAGCCATCCTGT GTGCCCCTGATGCGATGCGGGGGCTGCT GCA
SLC2A1 (GLUT-1)	qHsaCID0022232	ATGTCTGGTTGTAGAACTCCTCGATCACC TTCTGGGGGGCATTGATGACTCCAG TGTTGTAGCCAAACTGCAGGGAGCCAAG CACTGCTC



Supplementary Figure 1. mRNA levels of GLUT1 in subcutaneous adipose tissue from non-OSA, OSA therapeutic c-PAP and OSA sub-therapeutic c-PAP obese subjects at baseline and after 24 weeks of c-PAP treatment. Subcutaneous adipose tissue biopsies were obtained from non-OSA (white bars), OSA therapeutic c-PAP (black bars) and OSA sub-therapeutic c-PAP (grey bars) obese subjects at baseline (panel A) and after 24 weeks of treatment (panel B). Total RNA was extracted, and mRNA levels of GLUT1 were determined by qRT-PCR and normalized to 18S rRNA. Results are mean \pm SE of values in adipose tissue (n=2 measurements for each subject; 4 non-OSA, 6 OSA therapeutic c-PAP and 10 OSA sub-therapeutic c-PAP). Differences between groups were assessed with one-way ANOVA statistical analysis.

CD36**CD68****ERO-1****CD36****CD68****ERO-1**

Supplementary Figure 2. Relationship between ESS and adipose tissue inflammation at baseline and after c-PAP treatment. *Top panels:* correlation between ESS and mRNA levels of CD36, CD68 and ERO1 in OSA obese subjects at baseline (n=16 OSA therapeutic c-PAP subjects and n=15 OSA sub-therapeutic c-PAP subjects). *Bottom panels:* correlation between ESS and mRNA levels of CD36, CD68 and ERO1 in OSA obese subjects after c-PAP treatment (n=16 OSA therapeutic c-PAP subjects and n=15 OSA sub-therapeutic c-PAP subjects). Statistical analysis was performed using Pearson correlation.